Commonwealth Bank announces the sale of its 37.5% equity interest in BoComm Life Insurance Company Limited (“BoComm Life”) to Mitsui Sumitomo Insurance Co., Ltd (“MSI”) for RMB 3.2 billion ($668 million)
The Transaction is expected to result in an indicative after tax gain on sale of approximately $450 million. The carrying value of Commonwealth Bank’s equity interest in BoComm Life was $150 million as at 31 December 2017.
Chief Executive Officer Matt Comyn said: “This Transaction represents a further step in simplifying and focusing our portfolio and follows the announcement of the proposed sale of the Group’s life insurance businesses in Australia and New Zealand to AIA Group, and the strategic review of the Group’s life insurance business in Indonesia.”
Prior to completion of the Transaction, BoComm Life is intending to undertake a capital increase, for which Commonwealth Bank’s pro rata contribution will be RMB 1.125 billion ($235 million). This amount will be separately reimbursed in full by MSI on completion of the Transaction.
The expected impact to the Common Equity Tier 1 (“CET1”) ratio from the transactions is a net increase of 13 basis points, comprising an initial 5 basis point reduction at the time of the capital contribution and an 18 basis point increase upon completion of the sale of the BoComm Life equity interest.
Completion of the sale of the BoComm Life equity interest is subject to the China Banking and Insurance Regulatory Commission’s regulatory approval process, Chinese merger clearance and completion of the BoComm Life capital increase.
The completion of the Transaction will satisfy a condition to the sale of Commonwealth Bank’s life insurance businesses in Australia and New Zealand to AIA Group, which also remain subject to regulatory approvals in Australia and New Zealand.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.